1 d - übersetzen

Pancreatic Cancer Drug Combo Shows Strong Early Response

Updated trial results show a strong response for a new first-line combination treatment for metastatic pancreatic cancer. The combination pairs the daily oral drug daraxonrasib, sold as RASONQUE, with gemcitabine and nab-paclitaxel chemotherapy. In 61 patients with treatment-naive metastatic pancreatic adenocarcinoma, the confirmed response rate reached 60.7 percent. Complete responses, where scans showed no sign of cancer, occurred in 8.2 percent of patients. Disease control reached 90.2 percent, median duration of response was 11.1 months and median progression-free survival was 12.8 months. Twelve-month overall survival was 76.6 percent after a median follow-up of 18.3 months. The safety profile matched what doctors already knew from daraxonrasib and chemotherapy alone. The results support the ongoing Phase 3 RASolute 303 trial, which is testing daraxonrasib alone and with chemotherapy against chemotherapy alone.

image
advertisement
"We will never ask you to login, or register through a third-party advertisement."